

List of Tables

Table 1.1 Various Gene Delivery Approaches used in Atherosclerosis.....	7
Table 1.2 Targeting Endothelial Cell.....	11
Table 2.1 Various Gene Delivery Approaches used in Atherosclerosis.....	34
Table 2.2 Receptors present on various hepatic cell and may be used for drug targeting.....	67
Table 3.1 Absorbance profile of pDNA.....	92
Table 3.2 Accuracy of the UV spectrophotometric method.....	93
Table 3.3 Interday and intraday precision of the UV spectrophotometric method.....	94
Table 3.4: Representative Data for the dsDNA Standard Curve and QuantiFluor® dye.....	95
Table 3.5 Accuracy of the Spectrofluorimetric method.....	96
Table 3.6 Relative band density of 200 ng pDNA.....	100
Table 3.7 Relative band densities at different pDNA concentrations.....	100
Table 3.8 Mean absorbance values of TNBS assay carried out at incubation period of 1 hr.....	104
Table 3.9 Accuracy of the TNBS assay of stearyl amine.....	105
Table 3.10 Interday and intraday precision of the TNBS assay of stearyl amine.....	105
Table 3.11 Accuracy of the TNBS assay of DSPE.....	107
Table 3.12 Intraday and interday precision of the TNBS assay of DSPE.....	107
Table 3.13 Accuracy of the Sakaguchi assay of Boc-arginine.....	109
Table 3.14 Intraday and interday precision of Sakaguchi assay of Boc-arginine.....	109

Table 4.1 Profile of plasmid DNA used in the study.....	120
Table 4.2 Recipe for the transformation buffer.....	120
Table 4.3 Results observed during transformation of plasmid DNA (APOE3 & EGFP) on agar plate.....	122
Table 4.4 Effect of various culture parameters on the plasmid recovery.....	129
Table 5.1 Nomenclature of different compounds and synthesized lipids	137
Table 5.2 % molar conjugated lipids in the reaction mixture after dialysis post reaction period	140
Table 5.3 % molar conjugated lipids in the reaction mixture after dialysis post reaction period	141
Table 5.4 Characteristic mass spectra observations of synthesized compounds and some of their reactants	145
Table 5.5 Physicochemical properties of different cationic lipids used in preparation of liposomes	147

Table 6.1 Effect of process parameters for lipid films.....	157
Table 6.2 Effect of process parameters on hydration of lipid films.....	159
Table 6.3 Optimization of SA based liposomes: Trial batches.....	161
Table 6.4 Optimization of DSPE based liposomes: Composition of trial batches with their particle size and its distribution characteristics (SA: 10 mole%)	170
Table 6.5 Various variables and responses involved in optimization.....	178
Table 6.6 Coded and actual levels of HSPC, EPC and Chol used in optimization	178
Table 6.7 Design Matrix for Calcium Chloride Loaded Liposome Optimization.....	180
Table 6.8 Summary of ANOVA results for Different Models	180
Table 6.9 ANOVA Table 6.for Quadratic Mixture Model	181
Table 6.10 Summary of ANOVA results for Quadratic Mixture Model.....	182
Table 6.11 Summary of ANOVA results for Different Models	191
Table 6.12 ANOVA for Quadratic Mixture Model	191
Table 6.13 Summary of ANOVA results for Quadratic Mixture Model.....	192
Table 6.14 Constraints Applied for Selection of Optimized Batch	200
Table 6.15 Optimized Batch Parameters Based on Desirability.....	202
Table 6.16 Predicted Responses of the Optimized Batch	203
Table 6.17 Experimental Confirmation of the Predicted Responses	203
Table 6.18 Particle size and Zeta potential characteristics of optimized liposomes and liposomes of modified DSPE.....	204
Table 6.19 Selection of Process Parameters for lipoplex preparation	210
Table 6.20 Optimization of formulation parameters – L/P ratio optimization for different PEGylated liposomes	215
Table 6.21 Assay of different liposomal formulations	222
Table 6.22 Effect of lyophilization on complexation efficiencies of lipoplexes	223
Table 6.23 Particle size and Zeta potential characteristics of optimized liposomes and their lipoplexes	224
Table 6.24 Effect of lyophilization on particle size and zeta potential of HDSPE lipoplexes	227
Table 6.25 Reconstitution time and water content of lyophilized lipoplexes.....	228
Table 6.26 Effect of lyophilization on complexation efficiencies of lipoplexes	228
Table 6.27 Particle size and Zeta potential characteristics of optimized lipoplexes and lipoplexes of modified DSPE.....	229

Table 7.1 Intact pDNA content of naked pDNA incubated with serum	244
Table 7.2 Intact pDNA content of PEGylated and non-PEGylated lipoplexes after incubation with serum	245
Table 8.1 Cell treatment parameters for FACS	269
Table 8.2 GFP expression after transfection with different lipoplexes against naked pDNA and Lipofectamine-2000 lipoplexes*	271
Table 8.3 Cell treatment parameters for confocal microscopy	275
Table 9.1 % molar conjugation in the reaction mixture after dialysis post reaction period	282
Table 9.2 Physicochemical characteristics of the lipoplexes	283
Table 9.3 GFP expression after transfection with ligand conjugated and non-conjugated lipoplexes against naked pDNA and Lipofectamine-2000 lipoplexes*	285
Table 10.1 Sighting Study: Dosing protocol	294
Table 10.2 Results of Sighting Study	294
Table 10.3 MTD Study: Dosing Protocol	294
Table 10.4 Results for Main test	295
Table 10.5 Atherogenic diet composition	296
Table 10.6 Animal groups for atherogenesis induction and treatment	298
Table 10.7 Lipid profile in mice prior to treatment	303
Table 10.8 Lipid profile in mice during treatment	306
Table 11.1 Stability Testing Conditions for Drug Product Intended for Storage in Refrigerator as per ICH Guideline Q1A(R2).	310
Table 11.2 Stability Testing Data of gHDSPE lipoplexes	312